Cargando…
Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia
There is no current approved therapy for the ultimately lethal neuro- and cardio-degenerative disease Friedreich's ataxia (FA). Finding minimally-invasive molecular biomarkers of disease progression and drug effect could support smaller, shorter clinical trials. Since we and others have noted a...
Autores principales: | Hayashi, Genki, Cortopassi, Gino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831832/ https://www.ncbi.nlm.nih.gov/pubmed/27078885 http://dx.doi.org/10.1371/journal.pone.0153574 |
Ejemplares similares
-
Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia
por: Hayashi, Genki, et al.
Publicado: (2014) -
The role of oxidative stress in Friedreich's ataxia
por: Lupoli, Federica, et al.
Publicado: (2017) -
Potential biomarker identification for Friedreich’s ataxia using overlapping gene expression patterns in patient cells and mouse dorsal root ganglion
por: McMackin, Marissa Z., et al.
Publicado: (2019) -
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia
por: Jasoliya, Mittal, et al.
Publicado: (2019) -
Drug Repositioning in Friedreich Ataxia
por: Rufini, Alessandra, et al.
Publicado: (2022)